Current Anticoagulation Recommendation for COVID-19 Patients

Authors

DOI:

https://doi.org/10.21776/ub.hsj.2021.002.04.1

Keywords:

Thromboembolic Events, Anticoagulants, COVID-19, Guidelines.

Abstract

Thromboembolic events in COVID-19 patients can be one of the factors that aggravate the disease and increase mortality. When severe hypoxemia and hypotension occur in COVID-19 patients, the possibility of embolism should be considered. As a result, anticoagulant therapy in COVID-19 patients has an essential role in lowering disease severity and mortality. Many studies report that giving anticoagulants to COVID-19 patients can reduce mortality. Therefore, it is important to understand the role and use of anticoagulant therapy in cases of COVID-19. Several guidelines that have been issued by several health organizations in the world and Indonesia can be used as guidelines for clinicians to start anticoagulant therapy in cases of COVID-19. Various anticoagulant drug regimens have also been recommended to be used both as prophylaxis and as therapy for thromboembolism that can occur after COVID-19 cases.

References

Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thrombo- embolism in patients with COVID-19: A systematic review and meta-analysis. Res Pract Thromb Haemost 2020;4(7):1178–91. 10.1002/rth2.12439

Cuker A, Tseng EK, Nieuwlaat R, et al. American Society of Hema- tology 2021 guidelines on the use of anticoagulation for thrombo- prophylaxis in patients with COVID-19. Blood Adv 2021;5(3):872–88. 10.1182/bloodadvances.2020003763

Burhan E, Susanto AD, Nasution SA, et al. Protokol Tatalaksana Covid-19. 4th ed. Jakarta: 2021.

AlHajri L, Gebran N. The Use of Low Molecular Weight Heparin for Venous Thromboembolism Prophylaxis in Medical Patients: How Much Are We Adherent to the Guidelines? Open J Intern Med 2015;05(04):81–91. 10.4236/ojim.2015.54012

European Society of cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. Eur Heart J 2020;1–115.

Atallah B, Mallah SI, AlMahmeed W. Anticoagulation in COVID-19. Eur Hear J - Cardiovasc Pharmacother 2020;6(4):260–1. https://- doi.org/10.1093/ehjcvp/pvaa036. 10.1093/ehjcvp/pvaa036

COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. Disponible en: https://- covid19treatmentguidelines.nih.gov/. Natl Inst Heal 2020;2019:130. https://www.covid19treatmentguide- lines.nih.gov/.

Downloads

Published

2021-10-31

Issue

Vol. 2 No. 4 (2021): Management of Thrombosis in Covid-19 Patient with Cardiovascular Disease

Section

Editorial

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).